

Novo Medi Sciences launches next-gen Varicella Vaccine built on advanced formulation

23 January 2026 | News

NEXIPOX PLUS® is approved by the Drugs Controller General of India (DCGI) for use from 12 months of age



Mumbai-based Novo Medi Sciences (Novo Group) has announced the launch of NEXIPOX PLUS®, the most recent innovation in Varicella vaccine since decades. NEXIPOX PLUS® has been developed with a clear focus on addressing the unique clinical, environmental, and operational needs of Indian patients and healthcare settings, making Novo Medi Sciences the only company to proactively upgrade varicella vaccine specifically for India.

Live attenuated varicella vaccines are inherently thermolabile, making formulation stability and potency retention critical to ensuring effective immunisation outcomes. Recognising the challenges posed by real-world Indian conditions, NEXIPOX PLUS® has been developed with 2X trehalose-based stabiliser system, representing a significant evolution in formulation that are result oriented.

By replacing conventional stabilisers such as gelatin and mannitol, the formulation enhances viral stability, preserves potency, and significantly reduces the risk of allergic reactions and antigen crystallisation-related issues, supporting more reliable vaccine performance across storage, handling, and administration.

The prevalence of chickenpox remains high in India, and the introduction of NEXIPOX PLUS® aligns with broader public health goals of reducing disease burden and improving vaccination compliance. Designed with affordability, scalability, and

operational reliability in mind, the vaccine supports adoption in private practice and strengthens the overall immunisation ecosystem.

NEXIPOX PLUS® is approved by the Drugs Controller General of India (DCGI) for use from 12 months of age. Backed by patented technology across 156 countries, the product reflects strong global regulatory readiness, with international expansion strategies being evaluated based on public health needs and sustainable supply considerations.